Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Orexigen Therapeutics
With that in mind, let's take a closer look at Orexigen's business and see what CAPS investors are saying about the stock right now.
Orexigen facts
| Headquarters (founded) | La Jolla, Calif. (since 2002) |
| Market Cap | $399.9 million |
| Industry | Biotechnology |
| Trailing-12-Month Revenue | $3.4 million |
| Management | CEO Michael Narachi (since 2009) Acting CFO Joseph Hagan (since 2011) |
| Return on Capital (average, past 3 years) | (51.4%) |
| Cash/Debt | $138.6 million / $0 |
| Competitors |
Abbott Labs Arena Pharmaceuticals GlaxoSmithKline |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 24% of the 262 All-Star members who have rated Orexigen believe the stock will underperform the S&P 500 going forward.
Just yesterday, one of those bears, jed71, cautioned Fools about getting too excited over Orexigen's recent speculation-fueled surge:
Obesity drug still not approved yet. Run up based on expectations and approval received by a different company, Arena Pharma, for a similar obesity drug. It will not hold the run up, because, well, [Orexigen] never holds these run ups.
If you want market-thumping returns, you need to protect your portfolio from any undue risk. Luckily, we've compiled a special free report for investors called "Discover the Next Rule-Breaking Multibagger," which uncovers another small-cap growth play with big potential. The report is 100% free, but it won't be around forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.
